New & Noteworthy

What's Wrong with the Annual Sales Kickoff: And How to Fix it

New ways for pharma to make sure its sales reps stay sharp amid a flood of new information and a more complex selling climate. By Duncan Lennox.

Marketing: Ready for the Next War?

How pharma companies can catch up to the requirements of the modern marketing model. By Faruk Capan.

2014: Reading Between the Lines

THE CALENDAR SAYS IT'S WRAP UP TIME, not just for gifts, but for some of the trends that shaped big Pharma—for good or bad—during the past year.

Express Scripts to Center Stage

Pharm Exec profiles Express Scripts' Chief Medical Officer, Dr. Steve Miller, whose rise to prominence as an articulate critic of drug industry prices symbolizes the growing clout of America's largest pharmacy benefit manager.

Europe

Tougher Times Ahead Under UK PPRS

Under the voluntary 2014 Pharmaceutical Price Regulation Scheme in the UK, member companies have to pay back if NHS spending on branded medicines goes over pre-agreed growth rates. With no growth allowed for 2014 and 2015, it was always going to be a matter of when and how much — not if — payments would be made.

EMA—a Pioneer Permanently At Bay

Agency's plan for reporting clinical trial data has sparked strong reactions from health campaigners, industry, and patients.

Eruptions on Europe's Drug-Pricing Horizon

The EU may have a new monitoring scheme for Iceland's volatile geology, but it should also heed the volcano that could blow apart its assumptions on drug pricing and reimbursement, says Reflector.

Ireland's Celtic Tiger: Back on the Hunt

Leaders from industry, government, and the CRO community examine Ireland's future as a magnet for life science investments, and what the nation must do to remain the leading exporter of finished pharmaceutical products.

Global

Country Report: Algeria

Once considered a healthcare backwater, Algeria's expanding pharmaceuticals market is taking the African continent by storm.

Ireland's Celtic Tiger: Back on the Hunt

Leaders from industry, government, and the CRO community examine Ireland's future as a magnet for life science investments, and what the nation must do to remain the leading exporter of finished pharmaceutical products.

Surviving the Emerging Market Price Wars: Three Myths & Three Lessons

How big Pharma stalwarts can avoid a corrosive battle of attrition with local competitors and instead obtain the long-term goal of a stable pricing environment.

"Market-Based" Price Controls In India?

Three strategic implications for pharma pricing strategies in India.

Growing Pains: The European Medicines Agency at 20

Reflector looks at the growing pains of the European Medicine Agency (EMA) as it faces the key policy challenges of 2014.

Takeda's Oncology Taskmaster

Millennium Takeda's new president, Anna Protopapas, explains the life choices that brought her from Cyprus to Cambridge—and a lead position in the hotly contested search to make cancer a treatable disease.

Strategy

Express Scripts to Center Stage

Pharm Exec profiles Express Scripts' Chief Medical Officer, Dr. Steve Miller, whose rise to prominence as an articulate critic of drug industry prices symbolizes the growing clout of America's largest pharmacy benefit manager.

ABC: A Burgeoning Giant Steps Out

AmerisourceBergen exemplifies the shift underway among pharma's supply chain drivers, best summarized as "follow the customer". Company veteran Peyton Howell tells us more.

The '3S' Framework for Post-Deal Growth

Rebecca Ashkenazy, Alex Chang, Cyndi Green, Ted Miller, and Christine de los Reyes discuss how the '3S' framework — science, synergy, and survival — can build more value in biopharmaceutical dealmaking.

Dane in America

Jesper Hoiland, Novo Nordisk's President for North America, assesses the challenges and opportunities during his first year at the helm of the diabetes franchise leader's biggest affiliate market.

Blogs

FDA Pushes Forward with Biosimilar Development

FDA has scheduled a public meeting in early January to assess and weigh the data on the first U.S. application for a biosimilar therapy.

Tougher Times Ahead Under UK PPRS

Under the voluntary 2014 Pharmaceutical Price Regulation Scheme in the UK, member companies have to pay back if NHS spending on branded medicines goes over pre-agreed growth rates. With no growth allowed for 2014 and 2015, it was always going to be a matter of when and how much — not if — payments would be made.

Compassionate Use Debate Heats Up

Patient access to critical experimental medicines continues to grab public attention, as states enact “Right-to-Try” laws and Congress eyes establishing a national policy to provide not-yet-approved therapies to terminally ill patients

Big Boosts for Ebola R&D

The development and approval of new vaccines and antivirals to contain and treat the Ebola virus outbreak has become a top priority for the federal government and Congress, as seen in new policies to spur R&D and added funding for these efforts.

PCORI to Compare Hep C Treatments

The Patient-Centered Outcomes Research Institute (PCORI) is launching a $50 million program to fund research on the comparative effectiveness of various approaches for diagnosing and treating hepatitis C.

News Update

Steady Growth in Colorectal Cancer Market Predicted for Asia-Pac

The Colorectal Cancer (CRC) therapeutics market in Asia-Pacific is set to increase in value, from $1.9 billion in 2013 to $2.9 billion by 2020, says a new report from GBI Research.

Fixing Wikipedia

Will Pharma join a growing effort to make the world's leading online health information resource more relevant to providers and safer for patients? Peter Houston reports.

Social Media: Have We Reached The Tipping Point?

For pharma marketers, the good news is recent advances in social media monitoring make it possible to listen to or engage with patients on social media websites.

Taking the Noise Out of Signal Detection

Scignal Plus Taking the Noise Out of Signal Detection

How to Implement an ePRO Strategy

How to Implement an ePRO Strategy

Regulatory

FDA Pushes Forward with Biosimilar Development

FDA has scheduled a public meeting in early January to assess and weigh the data on the first U.S. application for a biosimilar therapy.

Big Boosts for Ebola R&D

The development and approval of new vaccines and antivirals to contain and treat the Ebola virus outbreak has become a top priority for the federal government and Congress, as seen in new policies to spur R&D and added funding for these efforts.

PCORI to Compare Hep C Treatments

The Patient-Centered Outcomes Research Institute (PCORI) is launching a $50 million program to fund research on the comparative effectiveness of various approaches for diagnosing and treating hepatitis C.

Sales & Marketing

What's Wrong with the Annual Sales Kickoff: And How to Fix it

New ways for pharma to make sure its sales reps stay sharp amid a flood of new information and a more complex selling climate. By Duncan Lennox.

Digital's Place in the Pharma Marketing Mix

The rush to digital will continue at a fast clip, but marketers need to reacquaint themselves with their brands' audiences.

OTC Drug Advertising: Alfred Hitchcock Style

The legendary director's on-screen attitude to his TV show's sponsor, Bristol-Myers, caused some consternation—until the drugmaker saw the results.

Social Media and the In-House Counsel

What is and what should be keeping you up at night.

R&D

Pharmacies — A New Patient Education Opportunity

Kenneth Getz of the Tufts Center for the Study of Drug Development looks at leveraging pharmacists as a channel to raise clinical research literacy among patient communities.

Open Innovation in Pharma: Defining the Dialogue

There is much talk today about "open innovation" in business and research forums—but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector? Does it signal a change in the way pharmaceutical companies approach research and innovation?

Raising the Stakes in CNS

As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory.